US Stock MarketDetailed Quotes
SLN Silence Therapeutics
- 7.680
- +0.750+10.82%
Close Nov 21 16:00 ET
362.61MMarket Cap-4539P/E (TTM)
7.790High6.430Low1.12MVolume6.870Open6.930Pre Close8.21MTurnover4.66%Turnover RatioLossP/E (Static)47.21MShares27.72052wk High3.05P/B185.39MFloat Cap5.81052wk Low--Dividend TTM24.14MShs Float35.000Historical High--Div YieldTTM19.63%Amplitude4.545Historical Low7.302Avg Price1Lot Size
Silence Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -303.45%-19.66M | 67.81%-4.81M | 2.10%-7.5M | 13.43%-39.35M | 11.50%-11.87M | 48.19%-4.87M | -80.89%-14.96M | 46.74%-7.66M | -767.88%-45.46M | -508.07%-13.41M |
| Net income from continuing operations | -182.88%-30.16M | -45.22%-17.44M | 73.45%-3.37M | -6.21%-50.31M | 0.56%-14.97M | -14.31%-10.66M | 10.51%-12.01M | -32.40%-12.67M | -3.30%-47.37M | -34.05%-15.05M |
| Operating gains losses | -223.66%-737K | -93.91%19K | 58.33%133K | 202.52%2.16M | 23.80%1.17M | 363.72%596K | 368.97%312K | -26.32%84K | 133.77%713K | 77.21%941K |
| Depreciation and amortization | -8.00%115K | 0.85%119K | -10.45%120K | 3.32%498K | -14.18%121K | 9.65%125K | 3.51%118K | 18.58%134K | 12.88%482K | 113.64%141K |
| Other non cash items | 473.95%7.62M | -259.49%-882K | -250.95%-791K | 155.50%706K | -59.10%1.67M | 52.92%-2.04M | 182.66%553K | 249.71%524K | -3,128.57%-1.27M | 11,422.22%4.08M |
| Change In working capital | -86.62%491K | 246.91%10.18M | -115.55%-15.68M | -41.14%-11.66M | 78.38%-1.13M | 86.16%3.67M | -350.83%-6.93M | 6.24%-7.27M | -121.27%-8.26M | -179.18%-5.24M |
| -Change in receivables | -88.86%1.15M | 155.76%6.19M | -918.88%-8.2M | -34.25%-1.46M | 108.94%115K | 273.08%10.34M | -3,296.33%-11.11M | 64.11%-805K | -103.95%-1.09M | 29.40%-1.29M |
| -Change in payables and accrued expense | -806.38%-664K | 478.14%4.64M | -605.01%-2.12M | -96.96%44K | 132.86%757K | -96.89%94K | -132.03%-1.23M | 113.52%419K | -39.83%1.45M | -269.29%-2.3M |
| -Change in other current assets | 110.94%498K | -217.23%-1.89M | -173.46%-999K | 53.37%-1.97M | -165.55%-392K | -124.63%-4.55M | 176.41%1.61M | 298.25%1.36M | -818.54%-4.23M | 122.66%598K |
| -Change in other working capital | 77.60%-495K | -67.29%1.24M | 47.15%-4.36M | -88.18%-8.28M | 28.25%-1.61M | -23.12%-2.21M | 176.31%3.79M | -377.20%-8.25M | -152.56%-4.4M | -123.13%-2.25M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -303.45%-19.66M | 67.81%-4.81M | 2.10%-7.5M | 13.43%-39.35M | 11.50%-11.87M | 48.19%-4.87M | -80.89%-14.96M | 46.74%-7.66M | -767.88%-45.46M | -508.07%-13.41M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -239.81%-28.84M | 111.64%548K | -30,593.75%-39.03M | 199.32%16.43M | 102.33%382K | 49,214.29%20.63M | -13,351.43%-4.71M | 350.98%128K | -290.66%-16.54M | -468.69%-16.41M |
| Net PPE purchase and sale | -145.00%-49K | -2,333.33%-67K | --0 | 67.86%-45K | 66.67%-1K | 57.45%-20K | 103.33%3K | ---27K | 89.32%-140K | 99.43%-3K |
| Net intangibles purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | ---6K | -1,204.35%-300K | ---- |
| Net investment purchase and sale | -245.52%-29.25M | --0 | ---39.44M | 196.23%15.52M | --0 | --20.1M | -229,150.00%-4.59M | --0 | -261.25%-16.13M | -422.50%-16.13M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -239.81%-28.84M | 111.64%548K | -30,593.75%-39.03M | 199.32%16.43M | 102.33%382K | 49,214.29%20.63M | -13,351.43%-4.71M | 350.98%128K | -290.66%-16.54M | -468.69%-16.41M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -50.40%5.97M | -73.40%847K | 555,500.00%105.56M | -41.57%25.16M | 22,445.45%9.92M | -72.06%12.03M | 29,045.45%3.18M | 140.43%19K | 40.17%43.05M | 44K |
| Net issuance payments of debt | 0.00%-49K | -185.29%-97K | --0 | 8.42%-174K | 44.87%-43K | -226.67%-49K | 32.00%-34K | -2.13%-48K | 9.95%-190K | -7,700.00%-78K |
| Net common stock issuance | -50.31%6.34M | -70.67%944K | 167,226.87%112.11M | -41.42%25.33M | 7,512.30%9.29M | -70.39%12.76M | 8,151.28%3.22M | --67K | 39.83%43.24M | 12,100.00%122K |
| Net other financing activities | ---322K | --0 | ---6.55M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -50.40%5.97M | -73.40%847K | 555,500.00%105.56M | -41.57%25.16M | 22,445.45%9.92M | -72.06%12.03M | 29,045.45%3.18M | 140.43%19K | 40.17%43.05M | --44K |
| Net cash flow | ||||||||||
| Beginning cash position | 268.38%109.48M | 141.93%113.06M | -1.43%54.03M | -25.46%54.82M | -34.67%58.81M | -42.36%29.72M | -21.19%46.73M | -25.46%54.82M | 167.90%73.54M | 25.95%90.02M |
| Current changes in cash | -253.05%-42.53M | 79.25%-3.42M | 886.22%59.04M | 111.79%2.24M | 94.75%-1.56M | -17.34%27.79M | -98.22%-16.48M | 48.12%-7.51M | -141.02%-18.95M | -1,425.23%-29.78M |
| Effect of exchange rate changes | -483.44%-5M | 70.81%-155K | 97.92%-12K | -1,424.56%-3.02M | 40.68%-3.22M | -73.03%1.3M | -190.92%-531K | -348.28%-576K | 317.14%228K | -2,929.61%-5.42M |
| End cash Position | 5.34%61.95M | 268.38%109.48M | 141.93%113.06M | -1.43%54.03M | -1.43%54.03M | -34.67%58.81M | -42.36%29.72M | -21.19%46.73M | -25.46%54.82M | -25.46%54.82M |
| Free cash flow | -302.80%-19.71M | 67.34%-4.88M | 2.52%-7.5M | 14.16%-39.4M | 13.45%-11.87M | 48.24%-4.89M | -78.83%-14.95M | 46.52%-7.69M | -938.74%-45.9M | -397.68%-13.71M |
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data